ST receptor binding compounds and methods of using the same
First Claim
1. A conjugated compound comprising:
- a) a ST receptor binding moiety; and
b) an active moiety;
wherein said active moiety is a radiostable active agent.
1 Assignment
0 Petitions
Accused Products
Abstract
Conjugated compounds which comprises an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent, and a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive active moiety are disclosed. Methods of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent, and a therapeutically effective amount of a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radiostable active moiety are disclosed. Methods of radioimaging metastasized colorectal cancer cells comprising the steps of first administering to an individual suspected of having metastasized colorectal cancer cells, a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent, and conjugated compound that comprises an ST receptor binding moiety and a radioactive active moiety wherein the conjugated compound is present in an amount effective for diagnostic use in humans suffering from colorectal cancer and then detecting the localization and accumulation of radioactivity in the individual'"'"'s body are disclosed.
-
Citations
26 Claims
-
1. A conjugated compound comprising:
-
a) a ST receptor binding moiety; and
b) an active moiety;
wherein said active moiety is a radiostable active agent. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 25, 26)
-
-
12. A pharmaceutical composition comprising:
-
a) a pharmaceutically acceptable carrier or diluent, and, b) conjugated compound comprising;
i) a ST receptor binding moiety; and
ii) an active moiety wherein said active moiety is a radioactive agent and said conjugated compound is present in an amount effective for therapeutic or diagnostic use in humans suffering from colorectal cancer. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19)
-
-
20. A method of radioimaging metastasized colorectal cancer cells comprising the steps of administering to an individual a pharmaceutical composition comprising:
-
a) a pharmaceutically acceptable carrier or diluent, and b) conjugated compound comprising;
i) a ST receptor binding moiety; and
ii) an active moiety;
wherein said active moiety is a radioactive agent and said conjugated compound is present in an amount effective for diagnostic use in humans suffering from colorectal cancer.
-
-
21. A method of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition comprising:
-
a) a pharmaceutically acceptable carrier or diluent, and, b) conjugated compound comprising;
i) a ST receptor binding moiety; and
ii) an active moiety;
wherein said active moiety is a radiostable agent or radioactive agent and said conjugated compound is present in an amount effective for therapeutic or diagnostic use in humans suffering from colorectal cancer.
-
-
22. A method of delivery of a nucleic acid molecule to intestinal tract cells of an individual comprising the steps of administering to said individual a pharmaceutical composition comprising:
-
a) a pharmaceutically acceptable carrier or diluent, and, b) a composition comprising;
i) a ST receptor ligand; and
ii) a nucleic acid molecule.
-
-
23. A method of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual:
-
a) a conjugated compound comprising an ST receptor binding moiety and an enzyme; and
b) a prodrug which when processed by the enzyme is converted to a drug. - View Dependent Claims (24)
-
Specification